Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA

Documenti analoghi

• Correction to “Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA”
  Pubblicazione: (2025)
• Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
  di: Hyunjae Shin, et al.
  Pubblicazione: (2024)
• Kinetics of the hepatitis B core‐related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide
  di: Norio Itokawa, et al.
  Pubblicazione: (2024)
• Endoscopic management of primary sclerosing cholangitis
  di: Suguru Mizuno, et al.
  Pubblicazione: (2025)
• Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes
  di: Huey‐Ling Chen, et al.
  Pubblicazione: (2024)